The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

The aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65 patients treated with Atez/Bev for advanced HCC from 22 institutions in Turkey between S...

Descripción completa

Detalles Bibliográficos
Autores principales: Akyildiz, Arif, Guven, Deniz Can, Ozluk, Ahmet Anil, Ismayilov, Rashad, Mutlu, Emel, Unal, Olcun Umit, Yildiz, Ibrahim, Iriagac, Yakup, Turhal, Serdar, Akbas, Sinem, Bayram, Ertugrul, Telli, Tugba Akin, Turkoz, Fatma Paksoy, Ozcelik, Melike, Erciyestepe, Mert, Selvi, Oguzhan, Gulbagci, Burcu, Erturk, Ismail, Isleyen, Zehra Sucuoglu, Kahraman, Seda, Akdag, Mutianur Ozkorkmaz, Hamitoglu, Buket, Unek, Ilkay Tugba, Unal, Caglar, Hacibekiroglu, İlhan, Arslan, Cagatay, Azizy, Abdulmunir, Helvaci, Kaan, Demirci, Umut, Dizdar, Omer, Basaran, Mert, Goker, Erdem, Sendur, Mehmet Ali, Yalcin, Suayib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637501/
https://www.ncbi.nlm.nih.gov/pubmed/37960746
http://dx.doi.org/10.1097/MD.0000000000035950

Ejemplares similares

Ejemplares similares